Payment overview · 2025
General Payments
$866.72
51 reported records · 11 companies
Healthcare provider profile · identity verified
Krunal Jayantkumar Mehta, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · GLENDORA, CA · NPI 1982867602
Verified facts
What the public records show
CMS Open Payments records show Krunal Jayantkumar Mehta, M.D. received $866.72 in general payments during 2025 across 51 reported records.
AstraZeneca Pharmaceuticals LP accounted for 31.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Otezla, Rexulti, Xifaxan.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Otezla by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Lokelma by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Jardiance by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nexlizet by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Entresto by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $271.94 | 31.4% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $195.05 | 22.5% | 13 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $168.76 | 19.5% | 17 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $48.16 | 5.6% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $41.97 | 4.8% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $37.86 | 4.4% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $27.23 | 3.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $26.05 | 3.0% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $19.82 | 2.3% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.00 | 1.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.88 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $866.72 | 51 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $195.05 | 13 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $195.05 | 13 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $168.76 | 17 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $165.33 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $146.80 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $48.16 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $41.97 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $40.38 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $37.86 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $27.23 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $26.05 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $19.82 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 54 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 77 | exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
54 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
77 | 19 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
80 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 788 | 193 |
| Amlodipine Besylate | Amlodipine Besylate | 466 | 106 |
| Levothyroxine Sodium | Levothyroxine Sodium | 440 | 101 |
| Pantoprazole Sodium | Pantoprazole Sodium | 435 | 112 |
| Losartan Potassium | Losartan Potassium | 419 | 123 |
| Metformin Hcl | Metformin Hcl | 418 | 101 |
| Eliquis | Apixaban | 310 | 54 |
| Furosemide | Furosemide | 307 | 61 |
| Gabapentin | Gabapentin | 307 | 77 |
| Lisinopril | Lisinopril | 287 | 68 |
| Metoprolol Tartrate | Metoprolol Tartrate | 274 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 272 | 56 |
| Carvedilol | Carvedilol | 258 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 178 | 35 |
| Levetiracetam | Levetiracetam | 175 | 25 |
| Trazodone Hcl | Trazodone Hcl | 174 | 42 |
| Quetiapine Fumarate | Quetiapine Fumarate | 172 | 33 |
| Azithromycin | Azithromycin | 163 | 127 |
| Divalproex Sodium | Divalproex Sodium | 162 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 162 | 42 |
| Famotidine | Famotidine | 159 | 37 |
| Memantine Hcl | Memantine Hcl | 158 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 152 | 44 |
| Donepezil Hcl | Donepezil Hcl | 143 | 20 |
| Ibuprofen | Ibuprofen | 140 | 54 |
| Januvia | Sitagliptin Phosphate | 140 | 19 |
| Potassium Chloride | Potassium Chloride | 133 | 27 |
| Simvastatin | Simvastatin | 133 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 130 | 35 |
| Omeprazole | Omeprazole | 114 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 111 | 39 |
| Glipizide | Glipizide | 110 | 29 |
| Fenofibrate | Fenofibrate | 107 | 19 |
| Tramadol Hcl | Tramadol Hcl | 107 | 40 |
| Diclofenac Sodium | Diclofenac Sodium | 98 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 93 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 91 | 16 |
| Albuterol Sulfate | Albuterol Sulfate | 86 | suppressed |
| Prednisone | Prednisone | 86 | 49 |
| Amiodarone Hcl | Amiodarone Hcl | 85 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 81 | suppressed |
| Atenolol | Atenolol | 80 | 18 |
| Entresto | Sacubitril/Valsartan | 80 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 80 | 23 |
| Jardiance | Empagliflozin | 77 | 19 |
| Myrbetriq | Mirabegron | 77 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 74 | 21 |
| Trulicity | Dulaglutide | 74 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 73 | 25 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 70 | 13 |
| Buspirone Hcl | Buspirone Hcl | 69 | 14 |
| Olanzapine | Olanzapine | 67 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 66 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 65 | 31 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 65 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 65 | 22 |
| Mounjaro | Tirzepatide | 64 | 13 |
| Benztropine Mesylate | Benztropine Mesylate | 63 | suppressed |
| Lactulose | Lactulose | 63 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 62 | 21 |
| Alprazolam | Alprazolam | 60 | 12 |
| Nifedipine Er | Nifedipine | 59 | suppressed |
| Mirtazapine | Mirtazapine | 56 | 18 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 54 | 23 |
| Farxiga | Dapagliflozin Propanediol | 54 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 54 | 18 |
| Lorazepam | Lorazepam | 53 | 16 |
| Spironolactone | Spironolactone | 53 | 12 |
| Celecoxib | Celecoxib | 52 | 16 |
| Meclizine Hcl | Meclizine Hcl | 52 | 17 |
| Finasteride | Finasteride | 51 | 13 |
| Pregabalin | Pregabalin | 51 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | suppressed |
| Digoxin | Digoxin | 49 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 49 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 47 | 41 |
| Sertraline Hcl | Sertraline Hcl | 47 | 11 |
| Cephalexin | Cephalexin | 44 | 33 |
| Baclofen | Baclofen | 43 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 43 | suppressed |
| Glimepiride | Glimepiride | 42 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 42 | 15 |
| Meloxicam | Meloxicam | 40 | suppressed |
| Ozempic | Semaglutide | 40 | suppressed |
| Novolin R | Insulin Regular, Human | 39 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 39 | 16 |
| Tradjenta | Linagliptin | 39 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 39 | suppressed |
| Allopurinol | Allopurinol | 38 | suppressed |
| Novolog | Insulin Aspart | 38 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 37 | suppressed |
| Glucagon Emergency Kit | Glucagon Hcl | 37 | suppressed |
| Humulin R | Insulin Regular, Human | 37 | suppressed |
| Latanoprost | Latanoprost | 37 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 37 | suppressed |
| Naproxen | Naproxen | 37 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 36 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 36 | 17 |
| Glucagon Emergency Kit | Glucagon | 35 | 13 |
| Sucralfate | Sucralfate | 34 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 17 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 34 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 33 | suppressed |
| Lacosamide | Lacosamide | 33 | suppressed |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | 17 |
| Novolog Flexpen | Insulin Aspart | 30 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Risperidone | Risperidone | 30 | suppressed |
| Linzess | Linaclotide | 29 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 20 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 28 | suppressed |
| Clonazepam | Clonazepam | 28 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 28 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Timolol Maleate | Timolol Maleate | 27 | suppressed |
| Xifaxan | Rifaximin | 27 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Phenobarbital | Phenobarbital | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Lubiprostone | Lubiprostone | 22 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Humalog | Insulin Lispro | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 20 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Calcium Acetate | Calcium Acetate | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 19 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 18 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 13 |
| Lokelma | Sodium Zirconium Cyclosilicate | 18 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | 11 |
| Santyl | Collagenase Clostridium Hist. | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 12 |
| Nystatin | Nystatin | 17 | 13 |
| Calcitriol | Calcitriol | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 16 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 16 | suppressed |
| Rytary | Carbidopa/Levodopa | 16 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 15 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 14 | suppressed |
| Budesonide | Budesonide | 14 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 14 | 13 |
| Ertapenem | Ertapenem Sodium | 14 | suppressed |
| Estazolam | Estazolam | 14 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 14 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Acetylcysteine | Acetylcysteine | 12 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Misoprostol | Misoprostol | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Otezla | Apremilast | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Levocarnitine | Levocarnitine | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Tobramycin | Tobramycin | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $866.72 · 51 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AUSTEDO XR, BREZTRI, Dexcom G6 Transmitter, FARXIGA, GEMTESA, JARDIANCE, Kerendia, LEQVIO, NEXLETOL, OTEZLA, REPATHA, REXULTI, XIFAXAN | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error